Mostrar el registro sencillo del ítem
dc.contributor.author
Cotabarren, Ivana María
dc.contributor.author
Omar, Thamer A.
dc.contributor.author
Muzzio, Fernando Javier
dc.date.available
2021-08-27T02:13:58Z
dc.date.issued
2021-09-05
dc.identifier.citation
Cotabarren, Ivana María; Omar, Thamer A.; Muzzio, Fernando Javier; Binder-free twin-screw melt granulation: An effective approach to manufacture high-dose API formulations; Elsevier Science; International Journal Of Pharmaceutics; 606; 120886; 5-9-2021; 1-21
dc.identifier.issn
0378-5173
dc.identifier.uri
http://hdl.handle.net/11336/139051
dc.description.abstract
This study investigates the use of twin-screw binder-free melt granulation (BFMG) in the development of high- dose solid dose formulations for low melting point thermally stable drugs. Both ibuprofen and guaifenesin are examined. By granulating pure API powder, it is shown that BFMG can successfully be used to produce granules that contain 100% API. A design of experiments (DoE) response surface methodology was used to establish the design space for the end-product. The effects of the most relevant process variables (barrel operating temperature, powder feed rate, screw speed and screw configuration) on granule properties (outlet temperature, size distribution, morphology, flowability, compressibility, porosity) and tablet attributes (tensile strength and in-vitro dissolution) were thoroughly studied. Barrel temperature (alone or in interactions with the other variables) represented the most significant variable for both drugs since it governs the formation of granules by partial melting and subsequent agglomeration of the fed powder. Interestingly, the shear action originated by screw speed and screw configuration resulted in various significant responses depending on the drug substance, indicating that it can also be affected by the nature of the processed molecule. Flow properties were improved (i.e., lower Hausner ratio) for both drugs after formation of granules. Tabletability was also tested by preparing 600 mg tablets for all samples. Surprisingly, the resulting granules were highly compactible, requiring only 1% lubricant to form strong tablets containing 96% API and 3% disintegrant. The results also showed that tablets become harder as the granule size increased, especially for guaifenesin. As expected, in-vitro dissolution results indicated that tablets and capsules showed slightly slower dissolution rates than the granules.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Science
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
SOLID DOSAGE FORMS
dc.subject
BINDER FREE GRANULATION
dc.subject
TWIN SCREW GRANULATOR
dc.subject
MELT GRANULATION
dc.subject
HIGH-DOSE FORMULATIONS
dc.subject.classification
Otras Ciencias Naturales y Exactas
dc.subject.classification
Otras Ciencias Naturales y Exactas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.title
Binder-free twin-screw melt granulation: An effective approach to manufacture high-dose API formulations
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-08-13T16:16:42Z
dc.journal.volume
606
dc.journal.number
120886
dc.journal.pagination
1-21
dc.journal.pais
Países Bajos
dc.description.fil
Fil: Cotabarren, Ivana María. Universidad Nacional del Sur. Departamento de Ingeniería Química; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Planta Piloto de Ingeniería Química. Universidad Nacional del Sur. Planta Piloto de Ingeniería Química; Argentina. State University of New Jersey; Estados Unidos
dc.description.fil
Fil: Omar, Thamer A.. State University of New Jersey; Estados Unidos. University of Mosul; Iraq
dc.description.fil
Fil: Muzzio, Fernando Javier. State University of New Jersey; Estados Unidos
dc.journal.title
International Journal Of Pharmaceutics
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0378517321006918
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.ijpharm.2021.120886
Archivos asociados